0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global NF kB Inhibitors Pipeline Insights 2019
Published Date: February 2019
|
Report Code: DELV-Mech-41
Home | Market Reports | Business & Industrial | Pharmaceuticals & Biotech
Global NF kB Inhibitors Pipeline Insights 2019

Global NF kB Inhibitors Pipeline Insights 2019

Code: DELV-Mech-41
Report
February 2019
150 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures


"NF-κB Inhibitors- Pipeline Insights, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across NF-κB Inhibitors. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 12+ active products with more than 10 companies involved. Some of the key players include AMG0101 of AnGes MG and Bardoxolone methyl of Reata Pharmaceuticals, and BIIB098 of Alkermes/Biogen.

Products covered by Phase
• Phase III, Phase II, Phase I
• Pre-clinical
• Inactive (Dormant and Discontinued)

Overview of pipeline development activities for NF-κB Inhibitors
Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

Therapeutic segmentation of products for NF-κB Inhibitors
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this mechanism.

Methodology

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report

• Provides an overview of therapeutic pipeline activity for NF-κB Inhibitors across the complete product development cycle including all clinical and non-clinical stages
• It comprises of detailed profiles of NF-κB Inhibitors therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
• Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
• Coverage of dormant and discontinued pipeline projects across NF-κB Inhibitors

Reasons to Buy

• Establish a comprehensive understanding of the current pipeline scenario across NF-κB Inhibitors to formulate effective R&D strategies
• Assess challenges and opportunities that influence NF-κB Inhibitors R&D
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the products and use it for target finding, drug repurposing, and precision medicine
• Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for NF-κB Inhibitors to enhance and expand business potential and scope
• Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive and discontinued drugs

Executive Summary
Overview
Introduction
Structure
Mechanism of Action
Inducers
Repressors
Clinical Significance
NF-κB Inhibitors
Pipeline Therapeutics (Active Products)
Pipeline Therapeutics (Inactive Products)
Comparative Analysis
Late Stage Products (Phase III)
Comparative Analysis
AMG0101: AnGes MG
Product Description
Research and Development
Product Development Activities
The list continues….
Mid Stage Products (Phase II)
Comparative Analysis
CPI-0610: CONSTELLATION
Product Description
Research and Development
Product Development Activities
The list continues….
Early Stage Products (Phase I)
Comparative Analysis
Pre-clinical Stage Products
Comparative Analysis
Therapeutic Assessment: Active Products
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Inactive Products (Dormant & Discontinued Products)
Comparative Analysis
Appendix

List of Tables

Table 1: Total Products for NF κB Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical Stage Products
Table 6: Assessment by Stage and Product Type
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Inactive Products

List of Figures

Figure 1: Total Products for NF κB INHIBITORS
Figure 2: Late Stage Products (Phase III)
Figure 3: Mid Stage Products (Phase II)
Figure 4: Early Stage Products (Phase I)
Figure 5: Pre-clinical Stage Products
Figure 6: Assessment by Stage and Product Type
Figure 7: Assessment by Route of Administration
Figure 8: Assessment by Stage and Route of Administration
Figure 9: Assessment by Molecule Type
Figure 10: Assessment by Stage and Molecule Type
Figure 11: Inactive Products

SELECT A FORMAT
Added to Cart

Electronic (PDF)
$1250
This license allows only one user to access the PDF.

Electronic (PDF)
$2500
This license allows all the users of an enterprise residing in one location to access the PDF

Electronic (PDF)
$4000
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
SecuX Technology Inc

RELATED REPORTS

Global Barium Titanium Oxide Market Insights Forecast to 2028
Global Barium Titanium Oxide Market Insights, Forecast to 2028

120 Pages
Type: Report
Code: QYRE-Auto-9Z7409
Wed May 18 00:00:00 UTC 2022

Add to Cart

Global Aspetic Negative Pressure Pharmaceutical Isolators Market Insights Forecast to 2028
Global Aspetic Negative Pressure Pharmaceutical Isolators Market Insights, Forecast to 2028

120 Pages
Type: Report
Code: QYRE-Auto-0T7466
Fri May 13 00:00:00 UTC 2022

Add to Cart

Global Chemical API Market Insights and Forecast to 2028
Global Chemical API Market Insights and Forecast to 2028

Market Analysis and Insights Global Chemical API MarketThe global Chemical API market size is projected to reach US million by 2028 from US million in 2021 at a CAGR of during 20222028.Fully considering the economic change by this health crisis Bulk API accounting for of the Chemical API global market in 2021 is projected to value US million by 2028 growing at a revised CAGR in the postCOVID19 period.

120 Pages
Type: Report
Code: QYRE-Auto-28A10066
Tue May 03 00:00:00 UTC 2022

Add to Cart